An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | Aplastic Anemia & MDS International Foundation
  1. Treatments
  2. Clinical Trials
  3. An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Clinical Trial: NCT02610777

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
https://clinicaltrials.gov/ct2/show/NCT02610777
Purpose: 

The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in participants with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low-blast acute myelogenous leukemia.

Status: 
Recruiting
Study Date: 
Fri, 01/01/2016 to Fri, 12/01/2017
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Azacitidine
Intervention: 
Drug: Azacitidine Azacitidine intravenous or subcutaneous formulation. Drug: Pevonedistat Pevonedistat intravenous infusion.